Sutro Biopharma【STRO】銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

2.04

買値

2.03

売値

2.16

出来高

621,900

1.975 日の範囲 2.15

1.67 52 週間の範囲 6.13

時価総額

168.216M

前日終値

2.03

始値

2.00

時刻

2.08

最終取引時間

財務取引量

US$ 1,282,862

VWAP

2.0628

平均取引量 (3 か月)

1,080,228

発行済株式数

82,458,725

配当利回り

PER

-1.57

1 株当たり利益 (EPS)

-1.3

歳入

153.73M

純利益

-106.79M

Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated ce... Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. 詳細を表示

セクター

Biological Pds,ex Diagnstics

業界

Biological Pds,ex Diagnstics

ウェブサイト

www.sutrobio.com

本社

South San Francisco, California, USA

設立

Sutro Biopharma Inc is listed in the Biological Pds,ex Diagnstics sector of the ナスダック市場 with ticker STRO. The last closing price for Sutro Biopharma was US$2.03. Over the last year, Sutro Biopharma shares have traded in a share price range of US$ 1.67 to US$ 6.13.

Sutro Biopharma currently has 82,458,725 shares in issue. The market capitalisation of Sutro Biopharma is US$167.39 million. Sutro Biopharma has a price to earnings ratio (PE ratio) of -1.57.

Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...

Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scale

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Boehringer Ingelheim BioXcellence™ and Sutro Biopharma Inc. today announced that they successfully applied Sutro’s proprietary...

Form 8-K - Current report

Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer

- 32% objective response rate (ORR) in evaluable patients at the 5.2 mg/kg starting dose – the selected dose for randomized portion (Part 2) of ongoing registrational REFRαME-O1 trial - - These...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.16	8.51063829787	1.88	2.08	1.84	974104	1.99415165	CS
4	0.06	3.0303030303	1.98	2.15	1.67	862276	1.90942625	CS
12	-1.31	-39.1044776119	3.35	4.6	1.67	1080228	2.46285037	CS
26	-1.81	-47.012987013	3.85	5.17	1.67	798580	3.05444785	CS
52	-2.77	-57.5883575884	4.81	6.13	1.67	844348	3.67314567	CS
156	-7.8	-79.2682926829	9.84	10.98	1.67	667736	4.69561271	CS
260	-9.7	-82.6235093697	11.74	28.3	1.67	533286	7.97224245	CS

STRO - Frequently Asked Questions (FAQ)

What is the current Sutro Biopharma share price?

The current share price of Sutro Biopharma is US$ 2.04

How many Sutro Biopharma shares are in issue?

Sutro Biopharma has 82,458,725 shares in issue

What is the market cap of Sutro Biopharma?

The market capitalisation of Sutro Biopharma is USD 167.39M

What is the 1 year trading range for Sutro Biopharma share price?

Sutro Biopharma has traded in the range of US$ 1.67 to US$ 6.13 during the past year

What is the PE ratio of Sutro Biopharma?

The price to earnings ratio of Sutro Biopharma is -1.57

What is the cash to sales ratio of Sutro Biopharma?

The cash to sales ratio of Sutro Biopharma is 1.09

What is the reporting currency for Sutro Biopharma?

Sutro Biopharma reports financial results in USD

What is the latest annual turnover for Sutro Biopharma?

The latest annual turnover of Sutro Biopharma is USD 153.73M

What is the latest annual profit for Sutro Biopharma?

The latest annual profit of Sutro Biopharma is USD -106.79M

What is the registered address of Sutro Biopharma?

The registered address for Sutro Biopharma is 310 UTAH AVE., SUITE 150, SOUTH SAN FRANCISCO, CALIFORNIA, 94080

What is the Sutro Biopharma website address?

The website address for Sutro Biopharma is www.sutrobio.com

Which industry sector does Sutro Biopharma operate in?

Sutro Biopharma operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
NVNINVNI Group Ltd	US$ 4.38 (193.96%)	366.98M
EVAXEvaxion Biotech AS	US$ 5.99 (64.56%)	55.41M
ELABPMGC Holdings Inc	US$ 3.0901 (56.07%)	76.48M
PCLAPicoCELA Inc	US$ 4.60 (49.35%)	3.75M
GOEVCanoo Inc	US$ 0.475 (43.94%)	282.22M
GODNUGolden Star Acquisition Corporation	US$ 3.11 (-75.82%)	17.51k
GODNGolden Star Acquisition Corporation	US$ 2.93 (-65.67%)	902.76k
NXTTNext Technology Holding Inc	US$ 1.37 (-54.93%)	2.56M
SGLYSingularity Future Technology Ltd	US$ 1.625 (-38.45%)	917.77k
WHLRLWheeler Real Estate Investment Trust Inc	US$ 90.11 (-38.07%)	8
ACONAclarion Inc	US$ 0.0557 (28.94%)	811.91M
NVNINVNI Group Ltd	US$ 4.38 (193.96%)	366.98M
RIMEAlgorhythm Holdings Inc	US$ 0.0357 (4.69%)	284.97M
GOEVCanoo Inc	US$ 0.475 (43.94%)	282.22M
NVDANVIDIA Corporation	US$ 142.62 (-3.12%)	232.88M